Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602320 | 1.00 | SIGMAR1 (0.32) | SIGMAR1KCNQ3KCNQ2OPRL1 | |
| SCHEMBL602319 | 1.00 | SIGMAR1 (0.32) | SIGMAR1KCNQ3KCNQ2OPRL1 | |
| SCHEMBL1306189 | 0.86 | ALDH1A1 (0.35) | SIGMAR1OPRL1 | |
| SCHEMBL600511 | 0.85 | ACACB (0.32) | — | |
| SCHEMBL600684 | 0.83 | CHRM1 (0.35) | — | |
| SCHEMBL601629 | 0.83 | CHRM1 (0.35) | — | |
| SCHEMBL600683 | 0.83 | CHRM1 (0.35) | — | |
| SCHEMBL1306995 | 0.80 | ALDH1A1 (0.42) | SIGMAR1 | |
| SCHEMBL988772 | 0.80 | ALDH1A1 (0.39) | SIGMAR1 | |
| SCHEMBL601803 | 0.80 | TAAR1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | COOPER DAVID GWYN | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041028-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | SIGMAR1 19/4885KCNQ3 1523/4885KCNQ2 1262/4885 |
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | SIGMAR1 29/4885KCNQ3 2113/4885KCNQ2 1338/4885 |
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | SIGMAR1 20/4885KCNQ3 1484/4885KCNQ2 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.